HealthDay News — The FDA has approved mifepristone (Korlym, Corcept Therapeutics) to treat endogenous Cushing’s syndrome in patients with type 2 diabetes who have not responded to previous surgery or ...
On Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym ...
Zacks Investment Research on MSN
Will Korlym continue to aid CORT's growth in 2026 after a strong Q1?
Corcept Therapeutics’ CORT sole marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing’s ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...
Corcept Therapeutics Incorporated CORT recently announced the submission of a new drug application (NDA) to the FDA for its proprietary, selective cortisol modulator, relacorilant, to treat patients ...
Corcept stock jumps after the company announces plans to resubmit relacorilant's NDA for treating Cushing's syndrome.
A U.S. District Court judge in New Jersey ruled in favor of Teva Pharmaceuticals USA, determining that the Parsippany-based drugmaker’s planned generic version of Corcept Therapeutics’ treatment for ...
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best biotech stocks to buy according to Wall Street analysts. On November 25, H.C. Wainwright reiterated a Buy rating and a $145 price ...
Corcept Therapeutics’ CORT sole-marketed drug, Korlym (mifepristone), is approved for treating Cushing's syndrome or endogenous hypercortisolism. The company’s top line solely comprises product sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results